Magenta therapeutics reports fourth quarter and full-year 2020 financial results and recent program highlights

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended december 31, 2020 and recent program highlights. “building on our momentum from 2020, we continue to advance our portfolio with now two active phase 2 clinical trials evaluating mgta-145 plus plerixafor in patients
DNTH Ratings Summary
DNTH Quant Ranking